TY - Jour T1 - 吗啡改变呼吸控制，但不是其他关键的OSA表型：随机试验JF - 欧洲呼吸期刊Jo - Eur Respir J Do - 10.1183 / 13993003 - 1901344-2019 SP - 1901344 Au - Martins，Rodrigo T. Au - Carbery，Jayne C. Au - Wang，David Au - Rowsell，Luke Au - Grunstein，Ronald R. Au - Eckert，Danny J. Y1 - 2020 / 01/01 Ur - //www.qdcxjkg.com/content/early/2020 / 03/04 / 13993003.01344-2019.Abstract N2 - 意外表阿片类药物正在增加。这些经常在睡眠期间发生。类化甲如吗啡可能会恶化阻塞性睡眠呼吸暂停（OSA）。因此，患有OSA的人可能与吗啡造成的危害更大。可能的机制包括呼吸抑制和降低到咽部肌的驱动，以增加上气道塌陷。然而，吗啡对OSA的4关键表型原因的影响（上气道脾脏[pcrit]，咽部咽部肌肉响应性，呼吸道唤醒阈值和通风控制[循环增益]尚不清楚.2.TWentyo一种人与OSA（AHI根据双盲，随机的交叉设计（ACTRN12613000858796），在2晚（1周洗涤）上进行了= 7-67场事件·H-1）。参与者在一次访问和安慰剂上持续40毫克MS-。在非REM睡眠期间，将来自治疗水平的连续正气道压力（CPAP）进行短暂降低，以诱导气流限制，以量化4个表型特征。 CO2 was also delivered via nasal mask on therapeutic CPAP to quantify hypercapnic ventilatory responses during non-REM sleep.Compared to placebo, 40 mg of morphine did not change Pcrit (−0.1±2.4 versus −0.4±2.2 cmH2O, p=0.58), genioglossus muscle responsiveness (−2.2[−0.87 to −5.4] versus −1.2[−0.3 to −3.5]microV/cmH2O, p=0.22), or arousal threshold (−16.7±6.8 versus −15.4±6.0 cmH2O, p=0.41), but did reduce loop gain (−10.1±2.6 versus −4.4±2.1 dimensionless, p=0.04) and hypercapnic ventilatory responses (7.3±1.2 versus 6.1±1.5 L·min−1, p=0.006).Concordant with recent clinical findings, 40 mg of MS-Contin does not systematically impair airway collapsibility, pharyngeal muscle responsiveness or the arousal threshold in moderately severe OSA patients. However, consistent with blunted chemosensitivity, ventilatory control is altered.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Tomazini Martins reports grants from NHMRC, during the conduct of the study.Conflict of interest: Dr. Carberry reports grants from National Health and Medical Research Council (NHMRC) of Australia, NeuroSleep-Centre for Research Excellence, grants from NHMRC, during the conduct of the study.Conflict of interest: Dr. Wang reports grants from National Health and Medical Research Council of Australia (NHMRC), during the conduct of the study.Conflict of interest: Dr. Rowsell reports grants from National Health and Medical Research Council of Australia (NHMRC), during the conduct of the study.Conflict of interest: Dr. Grunstein reports grants from National Health and Medical Research Council of Australia (NHMRC), during the conduct of the study; grants from Collaborative Research Centre (CRC) Consortium Grant between the Australian Government, Academia and Industry, other from Teva, other from Merck, outside the submitted work.Conflict of interest: Dr. Eckert reports grants from National Health and Medical Research Council of Australia (NHMRC), during the conduct of the study; grants and personal fees from Bayer, grants and personal fees from Apnimed, grants from Collaborative Research Centre (CRC-P) Consortium Grant between the Australian Government, Academia and Industry, outside the submitted work. ER -